Science & health
UK regulator warns of blood-ketone test-strip shortages after quality failures
The UK medicines regulator warns that quality-control failures have prompted Nova Biomedical to recall specified StatStrip ketone test-strip lots and pause distribution. Replacement UK stock is not expected for about four weeks, while additional lots could be withdrawn if they fail testing. The disruption may reduce rapid blood-ketone testing capacity, particularly for people with suspected or established diabetic ketoacidosis. Healthcare organisations are told to identify affected stock, validate alternatives and prioritise testing for patients at greatest risk. The notice concerns potential service disruption, not evidence that every strip is defective.
Editorial summary · Publisher article
What matters
- Specified lots should not be used and must be disposed of according to local procedures.
- Additional lots may become unavailable after repeated quality-control failures.
- The regulator says shortages could delay diagnosis, escalation or monitoring of diabetic ketoacidosis.
- Services are advised to assess stock, validate alternative testing and document contingency plans.
Highest-risk settings
The notice identifies emergency, paediatric, ambulance, community and other services as potentially affected, especially where laboratory testing is not immediately available.
Context & caveats
- The notice does not identify the affected lot numbers in the supplied text.
- Patients are advised to follow their existing insulin and sick-day plans and contact healthcare professionals with concerns.
Why this made the edition
A detailed regulator notice documents recalled lots, a likely four-week UK supply interruption and concrete clinical risks and mitigations for blood-ketone testing.
Source material